Skip to main content

Staphylococcus Aureus Infection

4
Pipeline Programs
6
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

6 companies ranked by most advanced pipeline stage

MSD
MSDIreland - Ballydine
1 program
1
Comparator: PlaceboPhase 2
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
1 program
1
Comparator: PlaceboPhase 21 trial
Active Trials
NCT00572910Completed206Est. Jan 2010
Destiny Pharma
Destiny PharmaUK - Brighton
1 program
1
XF-73 nasal gelPhase 1/21 trial
Active Trials
NCT02282605Completed60Est. Nov 2014
Armata Pharmaceuticals
Armata PharmaceuticalsLOS ANGELES, CA
1 program
1
AB-SA01Phase 12 trials
Active Trials
NCT03395769No Longer Available
NCT02757755Completed12Est. Aug 2016
Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
1 program
Medium enriched for newly synthesized antibodies in spine infectionN/A1 trial
Active Trials
NCT04897971Enrolling By Invitation200Est. May 2026
Merck & Co.
Merck & Co.RAHWAY, NJ
1 program
Comparator: PlaceboPHASE_2

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Sharp TherapeuticsComparator: Placebo
Destiny PharmaXF-73 nasal gel
Armata PharmaceuticalsAB-SA01
Colorado TherapeuticsMedium enriched for newly synthesized antibodies in spine infection

Clinical Trials (5)

Total enrollment: 478 patients across 5 trials

NCT00572910Sharp TherapeuticsComparator: Placebo

A Study to Evaluate the Safety and Immunogenicity of V710 in Adults With Kidney Disease on Hemodialysis (V710-005)(COMPLETED)

Start: Aug 2008Est. completion: Jan 2010206 patients
Phase 2Completed
NCT02282605Destiny PharmaXF-73 nasal gel

Study of the Nasal Decolonisation of Staphylococcus Aureus (SA) and the Safety and Tolerability of XF-73 Nasal Gel in Healthy Subjects

Start: Sep 2014Est. completion: Nov 201460 patients
Phase 1/2Completed
NCT02757755Armata PharmaceuticalsAB-SA01

Ascending Dose Study of the Safety of AB-SA01 When Topically Applied to Intact Skin of Healthy Adults

Start: May 2016Est. completion: Aug 201612 patients
Phase 1Completed
NCT03395769Armata PharmaceuticalsAB-SA01

Individual Patient Expanded Access for AB-SA01, an Investigational Anti-Staphylococcus Aureus Bacteriophage Therapeutic

N/ANo Longer Available
NCT04897971Colorado TherapeuticsMedium enriched for newly synthesized antibodies in spine infection

Serum Based Diagnosis of and Monitoring of Infection Recovery in Orthopedic Spine Implant Infections

Start: Aug 2021Est. completion: May 2026200 patients
N/AEnrolling By Invitation

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.